


Share of New Medicines Reimbursed by Public Insurance for All vs. Some Approved Indications (of all new medicines first launched globally within the past 10 years)



Source: PhRMA analysis of IQVIA MIDAS®, GlobalData Drug Pricing Intelligence, and country government data on regulatory approval, pricing and reimbursement decisions, April 2026.

Note: New medicines refers to all global new active substances first launched globally within the past 10 years (January 1, 2016 to December 31, 2025) and approved by the U.S. Food and Drug Administration, European Medicines Agency and/or Japan's Pharmaceuticals and Medical Devices Agency. A medicine is considered publicly reimbursed in Canada if 50% or more of the population lives in a province where it is publicly reimbursed. Restricted access refers to the lack of public insurance coverage for all approved indications and uses.